Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 8Neoplasm Metastasis 5Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumor 3Stomach Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Glioblastoma 2Sarcoma 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Liver Neoplasms 1Leukemia 1Kidney Neoplasms 1Hypertension 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Colonic Neoplasms 1Choriocarcinoma 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma 1Breast Neoplasms 1Brain Neoplasms 1Advanced Tumor 1Advanced Solid Malignancies 1Advanced Prostate Adenocarcinoma 1Advanced Breast Cancer 1

Interventions

pembrolizumab 14Nivolumab 13Sunitinib 12Axitinib 9cabozantinib 8belzutifan 8Ipilimumab 7Everolimus 5atezolizumab 4Sorafenib 4temsirolimus 3perifosine 3motexafin gadolinium 3Drug Therapy 3spartalizumab 2palbociclib 2liposomal doxorubicin 2lenvatinib 2entinostat 2ciforadenant 2belinostat 2avelumab 2Paclitaxel 2Immunotherapy 2G250 monoclonal antibody 2Fluorouracil 2Docetaxel 2Dexamethasone 2Cetuximab 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Kidney Neoplasms × cediranib × Clear all
NCT00423332 2017-02-02

Cediranib (AZD2171, RECENTINâ„¢) in Metastatic or Recurrent Renal Cell Carcinoma

AstraZeneca

Phase 2 Completed
105 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡